<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; are</title>
	<atom:link href="http://www.tapanray.in/tag/are/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>“Pharmaceutical Marketing Malpractices are Barriers to Healthcare Access” &#8211; The Relevance of Government Code of Ethical Marketing Practices in India</title>
		<link>http://www.tapanray.in/pharmaceutical-marketing-malpractices-are-barriers-to-healthcare-access-the-relevance-of-government-code-of-ethical-marketing-practices-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-marketing-malpractices-are-barriers-to-healthcare-access-the-relevance-of-government-code-of-ethical-marketing-practices-in-india</link>
		<comments>http://www.tapanray.in/pharmaceutical-marketing-malpractices-are-barriers-to-healthcare-access-the-relevance-of-government-code-of-ethical-marketing-practices-in-india/#comments</comments>
		<pubDate>Mon, 23 Jul 2012 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=62</guid>
		<description><![CDATA[Last week (July 19, 2012), most of the leading English business dailies of India reported that much-awaited “Uniform Code of Pharmaceutical Marketing Practices (UCPMP)” authored by the Department of Pharmaceuticals, quite in line with the amended guidelines for the Medical &#8230; <a href="http://www.tapanray.in/pharmaceutical-marketing-malpractices-are-barriers-to-healthcare-access-the-relevance-of-government-code-of-ethical-marketing-practices-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-marketing-malpractices-are-barriers-to-healthcare-access-the-relevance-of-government-code-of-ethical-marketing-practices-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The domestic API players are fast losing their dominance in the Indian API market</title>
		<link>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market</link>
		<comments>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/#comments</comments>
		<pubDate>Mon, 24 Oct 2011 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[dominance]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[losing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[their]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=184</guid>
		<description><![CDATA[There are two broad categories of markets for the Active Pharmaceutical Ingredients (API) across the world namely, highly regulated and semi regulated markets. Countries like, USA, Europe and Japan will fall under highly regulated category with high entry barriers for &#8230; <a href="http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-domestic-api-players-are-fast-losing-their-dominance-in-the-indian-api-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The top two reasons for not seeking medical treatment, across the population, are not poor ‘Access to Healthcare’ in India</title>
		<link>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india</link>
		<comments>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 07 Feb 2011 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Across]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[seeking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=305</guid>
		<description><![CDATA[“About 1.8 million children under age of 5 die in India every year; 68,000 mothers die due to maternal causes, and 52 million children in the country are stunted”. “With 70% people living in more than 600,000 villages across rural &#8230; <a href="http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-top-two-reasons-for-not-seeking-medical-treatment-across-the-population-are-not-poor-access-to-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Non-Communicable Diseases (NCD) are hitting the poor even harder, economically: a time to ponder and a time to act</title>
		<link>http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act</link>
		<comments>http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/#comments</comments>
		<pubDate>Mon, 06 Dec 2010 00:30:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Communicable]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economically]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[harder]]></category>
		<category><![CDATA[hitting]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[ponder]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=339</guid>
		<description><![CDATA[November 11, 2010 edition of &#8216;The Lancet&#8217; published an article titled, “Raising the priority of preventing chronic diseases: a political process&#8221;. The article enumerated the following: “Chronic diseases, especially cardiovascular diseases, diabetes, cancer, and chronic obstructive respiratory diseases, are neglected &#8230; <a href="http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/non-communicable-diseases-ncd-are-hitting-the-poor-even-harder-economically-a-time-to-ponder-and-a-time-to-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating an IPR friendly robust ‘Echo-System’ and &#8216;Improving Access to Affordable Medicines&#8217; are not either/or situation in India</title>
		<link>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india</link>
		<comments>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/#comments</comments>
		<pubDate>Mon, 13 Sep 2010 01:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Eco-System]]></category>
		<category><![CDATA[either/or]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Improving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[situation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=375</guid>
		<description><![CDATA[Last year, though the growth of the Global Pharmaceutical Industry with a turnover of US$ 752 billion significantly slowed down to just 6.7% due to various contributing factors, the Indian Pharmaceutical Industry continued to maintain a robust of growth of &#8230; <a href="http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-an-ipr-friendly-robust-echo-system-and-improving-access-to-affordable-medicines-are-not-eitheror-situation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making quality medicines available at an affordable price – Are we &#8216;missing woods for the trees&#8217;?</title>
		<link>http://www.tapanray.in/making-quality-medicines-available-at-an-affordable-price-are-we-missing-woods-for-the-trees/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-quality-medicines-available-at-an-affordable-price-are-we-missing-woods-for-the-trees</link>
		<comments>http://www.tapanray.in/making-quality-medicines-available-at-an-affordable-price-are-we-missing-woods-for-the-trees/#comments</comments>
		<pubDate>Mon, 16 Aug 2010 01:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[at]]></category>
		<category><![CDATA[available]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[trees]]></category>
		<category><![CDATA[we]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[woods]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=387</guid>
		<description><![CDATA[On August 4, 2010 the Parliamentary standing committee for Health and Family Welfare in its 45th report, recommended the following to the ‘Rajya Sabha’ of the Parliament of India for ‘Making quality medicines available at an affordable price’ to the &#8230; <a href="http://www.tapanray.in/making-quality-medicines-available-at-an-affordable-price-are-we-missing-woods-for-the-trees/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-quality-medicines-available-at-an-affordable-price-are-we-missing-woods-for-the-trees/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The traditional &#8216;Business Models&#8217; of R&amp;D focused Global Pharmaceutical majors are undergoing a metamorphosis</title>
		<link>http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis</link>
		<comments>http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/#comments</comments>
		<pubDate>Mon, 02 Aug 2010 00:30:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[undergoing]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=393</guid>
		<description><![CDATA[Mounting pressure on the P&#38;L account, as the products go off patent: Patented new products are the prime growth driver of the research based pharmaceutical companies of the world. Since last few years, because of various reasons, the number of &#8230; <a href="http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Path-breaking medicines are just not enough… a comprehensive healthcare reform in India is long overdue</title>
		<link>http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue</link>
		<comments>http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/#comments</comments>
		<pubDate>Mon, 14 Jun 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[comprehensive]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequalities]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[just]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[overdue]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Path-breaking]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=415</guid>
		<description><![CDATA[The Prime Minister of India, Dr. Manmohan Singh reiterated the following in his speech at the 30th Convocation of PGIMER, Chandigarh on November 3, 2009: ”As in economics, so as in medicine too, it is easy to get lost in &#8230; <a href="http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Challenges for the Pharmaceutical Industry in the new paradigm – there are more questions than answers</title>
		<link>http://www.tapanray.in/challenges-for-the-pharmaceutical-industry-in-the-new-paradigm-there-are-more-questions-than-answers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=challenges-for-the-pharmaceutical-industry-in-the-new-paradigm-there-are-more-questions-than-answers</link>
		<comments>http://www.tapanray.in/challenges-for-the-pharmaceutical-industry-in-the-new-paradigm-there-are-more-questions-than-answers/#comments</comments>
		<pubDate>Mon, 19 Apr 2010 01:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[there]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=439</guid>
		<description><![CDATA[To get insight into the future challenges of the pharmaceutical industry in general ‘Complete Medical Group’of U.K recently conducted a study with a sizeable number of senior participants from the pharmaceutical companies of various sizes and involving many countries. The &#8230; <a href="http://www.tapanray.in/challenges-for-the-pharmaceutical-industry-in-the-new-paradigm-there-are-more-questions-than-answers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/challenges-for-the-pharmaceutical-industry-in-the-new-paradigm-there-are-more-questions-than-answers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bt Bringal…health and food safety…agricultural independence…biodiversity, are all intertwined</title>
		<link>http://www.tapanray.in/bt-bringalhealth-and-food-safetyagricultural-independencebiodiversity-are-all-intertwined/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=bt-bringalhealth-and-food-safetyagricultural-independencebiodiversity-are-all-intertwined</link>
		<comments>http://www.tapanray.in/bt-bringalhealth-and-food-safetyagricultural-independencebiodiversity-are-all-intertwined/#comments</comments>
		<pubDate>Mon, 15 Mar 2010 00:30:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agricultural]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[biodiversity]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bringal]]></category>
		<category><![CDATA[Bt]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[intertwined]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=455</guid>
		<description><![CDATA[Bacillus Thuringiensis (Bt) Brinjal has now become a subject of intensive debate for various important reasons. Bt Bringal is a genetically modified strain of Brinjal, developed by the premier seed company in India Mahyco in collaboration with the American major &#8230; <a href="http://www.tapanray.in/bt-bringalhealth-and-food-safetyagricultural-independencebiodiversity-are-all-intertwined/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/bt-bringalhealth-and-food-safetyagricultural-independencebiodiversity-are-all-intertwined/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
